罗格列酮对非糖尿病代谢综合征患者血清脂联素水平和胰岛素抵抗的影响

目的探讨脂联素对非糖尿病代谢综合征患者的治疗作用。方法将92例非糖尿病代谢综合征患者分成A、B两组。A组给予饮食控制及常规降血压:调脂治疗;B组在上述治疗基础上,加用罗格列酮4 mg/d。结果两组服药前,B组空腹血糖水平略高于A组。服药后,B组脂联素水平、ISI较A组升高;Homa-IR较A组降低,其差异均有统计学意义(均P<0.01)。结论罗格列酮可增加胰岛素的敏感性,从而改善非糖尿病代谢综合征患者的代谢成分异常聚集的病理状态而产生治疗的正性作用。

Effect of rosiglitazone on serum adiponectin level and insulin resistance in non-diabetic metabolic syndrome patients

Objective To explore the effect of rosiglitazone on serum adiponectinlevel and isulin resistance in patients with non-diabetic metabolic syndrome.Methods 92 patients with non-diabetic metabolic syndrome were divided into group A and group B.Group A was asked to control diet and lower blood pressure and adjust blood lipids with regular therapy.On this basis,group B was asked to add oral administration of rosiglitazone,4mg / day.Results Before treatment,the fasting blood glucose levels in group B were slightly higher than group A.The levels of adiponectin and ISI showed higher in group B than group A after medication.however,Homa-IR lowered significantly in group B than group A,P0.001.Conclusion Rosiglitazone improves insulin sensitivity and its abnormal metabolic components in patient with metabotic syndrome.